Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.44 |
| ▸ | SPTLC2 | O15270 | 6/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | F2R | P25116 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154345 | 1.00 | TACR1 (0.44) | TACR1SPTLC2CCR2F2RTAS1R3 | |
| SCHEMBL4148357 | 0.93 | SPTLC2 (0.40) | TACR1SPTLC2CCR2F2RTAS1R3 | |
| SCHEMBL4148360 | 0.93 | SPTLC2 (0.40) | TACR1SPTLC2CCR2F2RTAS1R3 | |
| SCHEMBL4141816 | 0.91 | KCNH2 (0.46) | TACR1TACR2 | |
| SCHEMBL4141820 | 0.91 | KCNH2 (0.46) | TACR1TACR2 | |
| SCHEMBL4153321 | 0.91 | SPTLC2 (0.48) | TACR1SPTLC2CCR2F2R | |
| SCHEMBL4163875 | 0.90 | RHOC (0.49) | SPTLC2CCR2F2R | |
| SCHEMBL4162645 | 0.90 | SPTLC2 (0.41) | TACR1SPTLC2CCR2F2R | |
| SCHEMBL4162644 | 0.90 | SPTLC2 (0.41) | TACR1SPTLC2CCR2F2R | |
| SCHEMBL4163877 | 0.90 | RHOC (0.49) | SPTLC2CCR2F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | TACR1 9/4885SPTLC2 3640/4885CCR2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.